{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Antigen[C268]" in comments (approximate match)
Status:
US Approved Rx
(2009)
First approved in 2006
Source:
BLA125126
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
First approved in 2006
Source:
BLA125126
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
First approved in 2002
Source:
BLA103666
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1970)
First approved in 1970
Class:
PROTEIN
Status:
US Approved Rx
(2005)
First approved in 1970
Class:
PROTEIN
Status:
Investigational
Source:
NCT02833506: Phase 1 Interventional Withdrawn Recurrent Fallopian Tube Carcinoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00019682: Phase 3 Interventional Completed Recurrent Melanoma
(1999)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125324
(2010)
Source URL:
First approved in 2010
Source:
BLA125324
Source URL:
Class:
PROTEIN
